Cowen Starts Achaogen (AKAO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
William Blair Starts Achaogen (AKAO) at Outperform
April 7, 2014 4:26 PM EDTWilliam Blair initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreCredit Suisse Starts Achaogen (AKAO) at Outperform
April 7, 2014 7:31 AM EDTCredit Suisse initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreNeedham & Company Starts Achaogen (AKAO) at Buy
April 7, 2014 7:17 AM EDTNeedham & Company initiates coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $21.00.
Analyst Alan Car comments, "Lead drug plazomicin is under development for the treatment of infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). A Phase 3 trial... More
